Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
Not Applicable
Recruiting
- Conditions
- Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 146
- Registration Number
- NCT07047586
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
Not Applicable
Not yet recruiting
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 48
- Registration Number
- NCT07041437
- Locations
- 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China
Sarcopenia and Peripheral Artery Disease With Chronic Limb Threatening Ischemia
Completed
- Conditions
- SarcopeniaPeripheral Arterial DiseaseChronic Limb Threatening Ischemia
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 97
- Registration Number
- NCT07037979
- Locations
- 🇨🇳
Huadong Hospital, Fudan University, Shanghai, China
Risk and Prognosis of Brain Metastasis in Non-Small Cell Lung Cancer
Not yet recruiting
- Conditions
- NSCLC (Non-small Cell Lung Cancer)Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 2000
- Registration Number
- NCT07034365
Digoxin Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
Phase 1
Not yet recruiting
- Conditions
- Colorectal Carcinoma
- Interventions
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT07025850
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients
Phase 3
Not yet recruiting
- Conditions
- Breast CancerAdjuvant Therapy
- Interventions
- Drug: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)Drug: Standard endocrine therapy combined with CDK4/6 Inhibitor
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1903
- Registration Number
- NCT07019363
Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients
Phase 3
Not yet recruiting
- Conditions
- TNBCBreast Cancer
- Interventions
- Drug: Utidelone plus capecitabine
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 440
- Registration Number
- NCT07021261
RASi for Preventing Postoperative Recurrence of Stage II/III Colon Cancer
Completed
- Conditions
- Colon Cancer (Stage II &Amp;Amp; III)
- Interventions
- Drug: Renin-angiotensin system inhibitors (RASi)Drug: No renin-angiotensin system inhibitors (No RASi)
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 2640
- Registration Number
- NCT07012538
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer
Phase 3
Not yet recruiting
- Conditions
- Breast CancerAdjuvant Therapy
- Interventions
- Drug: ChemotherapyDrug: CDK4/6 InhibitorDrug: Endocrine therapy
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1244
- Registration Number
- NCT07005557
RGL-305+ Lymphoma + Exploratory Clinical Study
Not Applicable
Recruiting
- Conditions
- Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)
- Interventions
- Drug: RGL-305
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 12
- Registration Number
- NCT07006012
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China